Onconova Therapeutics is seeking the green light from the U.S. Food and Drug Administration (FDA) to begin a Phase 1 clinical trial for its small molecule ON 123300 in certain types of breast cancer. The trial would include, but not be limited to, people with relapsed/refractory advanced breast cancer, including those with hormone receptor-positive (HR ), human epidermal growth factor receptor 2-negative HER2-) metastatic breast cancer who are resistant to approved second-generation CDK4/6 inhibitors. “Once the FDA…
You must be logged in to read/download the full post.
The post Onconova Seeking FDA Approval for Phase 1 Trial of ON 123300 for Breast Cancer appeared first on BioNewsFeeds.